Covance, the drug development business of Laboratory Corporation of America Holdings (LabCorp), is the world’s most comprehensive drug development company, dedicated to advancing healthcare and delivering Solutions Made Real® by providing high-quality nonclinical, clinical and commercialization services to pharmaceutical and biotechnology companies to help reduce the time and costs associated with drug development. Because of our broad experience and specialized expertise, we’re in a unique position to supply insights that go above and beyond testing -- We have helped pharmaceutical and biotech companies develop each of the top 50 prescription drugs in the marketplace today. We also offer laboratory testing services to the chemical, agrochemical and food industries and are a market leader in toxicology services, central laboratory services, discovery services, and a top global provider of Phase III clinical trial management services. Together with our clients, we create solutions that transform potential into reality.
Type
Subsidiary
Parent Company
Laboratory Corporation of America Holdings
HQ
Princeton, US
Founded
1968
Covance was founded in 1968 and is headquartered in Princeton, US

Covance Office Locations

Covance has an office in Princeton

Covance Data and Metrics

Covance Summary

Founding Date

1968
Covance is a subsidiary of Laboratory Corporation of America Holdings

Covance Financial Metrics

Covance's revenue was reported to be $2.6 b in FY, 2013
Numbers are in $, USDFY, 2013

Revenue

2.6 b

Net Income

179.2 m
Numbers are in $, USDFY, 2013

Cash

617.7 m

Accounts Receivable

331.8 m

Inventories

201.6 m

Current Assets

1.5 b

PP&E

913.6 m

Goodwill

109.8 m

Total Assets

2.6 b

Accounts Payable

59.7 m

Current Liabilities

632.7 m

Additional Paid-in Capital

859.5 m

Retained Earnings

1.8 b

Total Equity

1.6 b

Financial Leverage

1.6 x
Numbers are in $, USDFY, 2013

Net Income

179.2 m

Depreciation and Amortization

127.9 m

Accounts Receivable

7.7 m

Inventories

(1.3 m)

Accounts Payable

25.3 m

Cash From Operating Activities

405.7 m

Capital Expenditures

(162.2 m)

Cash From Investing Activities

(253.5 m)

Cash From Financing Activities

(32.6 m)

Income Taxes Paid

14.3 m

Free Cash Flow

567.8 m

Covance Median Salaries

Source: 28 public H-1B filings from Covance

Covance Online and Social Media Presence

Covance Company Life and Culture

You may also be interested in